![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
X
20
S.a.l.a.r.s. S.p.a. Como It, based in U.S.A, is a pharmaceutical company.
One of their significant offerings is Dihydrocodeine hydrogen tartrate, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2004-187 - Rev 01
This Chemical Type CEP, issued on April 08, 2011, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1776 associated with this CEP further emphasizes